Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The Journal of Behavioral Health Services & Research
Published in: The Journal of Behavioral Health Services & Research 3/2013

01-07-2013

Variation in Use of Buprenorphine and Methadone Treatment by Racial, Ethnic, and Income Characteristics of Residential Social Areas in New York City

Authors: Helena B. Hansen, MD, PhD, Carole E. Siegel, PhD, Brady G. Case, MD, David N. Bertollo, BA, Danae DiRocco, MPH, Marc Galanter, MD

Published in: The Journal of Behavioral Health Services & Research | Issue 3/2013

Login to get access

Excerpt

Opiate agonist therapies for opiate dependence lower HIV incidence and arrest rates among injection drug users,1‐3 thus enhancing access to these treatments is a major public health priority. Buprenorphine, a partial opiate receptor agonist approved by the US FDA in 2002 for treatment of opiate dependence, offers important advantages over methadone maintenance. Buprenorphine is less lethal in overdose than methadone.4 The most commonly prescribed formulation of buprenorphine, in which it is combined with the opiate antagonist naloxone, produces opiate withdrawal when injected, limiting its abuse potential.5 Because of these lower risks, buprenorphine can be prescribed by office-based generalist physicians, potentially increasing treatment access and reducing stigma in comparison to methadone,6 which is restricted to federally regulated methadone clinics. …
Literature
1.
Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008;103(9):1493–4.CrossRef
2.
Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283(10):1303–10PubMedCrossRef
3.
Appel PW, Joseph H, Kott A, et al. Selected in-treatment outcomes of long-term methadone maintenance treatment patients in New York State. Mt. Sinai Journal of Medicine 2001;68(1):55–61
4.
Bell JR, Butler B, Lawrence A, et al. Comparing overdose mortality associated with methadone and buprenorphine. Drug and Alcohol Dependence 2009;104(1–2):73–7PubMedCrossRef
5.
6.
Merrill JO. Policy progress for physician treatment of opiate addiction. Journal of General Internal Medicine 2002;17(5):361–8PubMed
7.
Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addictive Behavior 2011 36(6):584–9CrossRef
8.
Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment Prevention and Policy 2008;3:17CrossRef
9.
Wallack SS, Thomas CP, Martin TC, et al. Substance Abuse Treatment Organizations as Mediators of Social Policy: Slowing the Adoption of a Congressionally Approved Medication. Journal of Behavioral Health Services & Research 2010;37(1):64–78CrossRef
10.
Roman PM, Abraham AJ, Rothrauff TC, et al. A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2010;38(Suppl 1):S44–S52PubMedCrossRef
11.
Browne-Miller A. The Praeger International Collection on Addictions. Westport, CT: Greenwood, 2009
12.
Benoit E, Young R, Magura S, et al. The impact of welfare reform on methadone treatment: policy lessons from service providers in New York City. Substance Use & Misuse 2004;39(13–14):2355–90CrossRef
13.
Morgenstern J, Hogue A, Dauber S, et al. A practical clinical trial of coordinated care management to treat substance use disorders among public assistance beneficiaries. J Consult Clin Psychol. 2009;77(2):257–69PubMedCrossRef
14.
Nunn A, Zeller N, Dickman S, et al. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug and Alcohol Dependence 2011;113(2–3):252CrossRef
15.
16.
Massey DS, Denton NA. American Apartheid: Segregation and the Making of the American Underclass. Cambridge, MA: Harvard University Press, 1993
17.
Fullilove MT. Rootshock: How Tearing Up City Neighborhoods Hurts America, and What We Can Do About It. New York: Random House, 2005
18.
Singer M. Introduction to Syndemics: A Critical Systems Approach to Public and Community Health. San Francisco: John Wiley & Sons, 2009
19.
Frank B. An overview of heroin trends in New York City: Past, present and future. The Mount Sinai Journal of Medicine 2000;67(5–6):340–6
20.
McNeely N, Gourevitch MN, Paone D, et al. Estimating the prevalence of illicit opioid use in New York City using multiple data sources. BMC Public Health 2012;12:443PubMedCrossRef
21.
22.
Courtwright DT. The prepared mind: Marie Nyswander, methadone maintenance, and the metabolic theory of addiction. Addiction 1997; 92(3):257–65.PubMedCrossRef
23.
Grubesic TH, Matisziw TC. On the use of ZIP codes and ZIP code tabulation areas (ZCTAs) for the spatial analysis of epidemiological data. International Journal of Health Geography 2006;5:58CrossRef
24.
Smith MP, Olatunde O, White C. Inequalities in disability-free life expectancy by area deprivation: England, 2001–04 and 2005–08. Health Statistics Quarterly 2010;48:36–57PubMedCrossRef
25.
Araujo EM, Costa Mda C, Oliveira NF, et al. Spatial distribution of mortality by homicide and social inequalities according to race/skin color in an intra-urban Brazilian space. Brazilian Review of Epidemiology (Rev Bras Epidemiol) 2010;13(4):549–60CrossRef
26.
Chau KL. Ecological analysis of health care utilization for China’s rural population: association with a rural county’s socioeconomic characteristics. BMC Public Health 2010;10:664PubMedCrossRef
27.
Bocquier A, Cortaredona S, Nauleau S, et al. Prevalence of treated diabetes: Geographical variations at the small-area level and their association with area-level characteristics. A multilevel analysis in Southeastern France. Diabetes Metab 2011;37(1):39–46PubMedCrossRef
28.
Das-Munshi J, Becares L, Dewey ME, et al. Understanding the effect of ethnic density on mental health: multi-level investigation of survey data from England. British Medical Journal 2010;341:c5367PubMedCrossRef
29.
Gottfredson DC, McNeil RJ, Gottfredson GD. Social area influences on delinquency: A multilevel analysis. Journal of Research in Crime and Delinquency 1991;28(2):197–226CrossRef
30.
Shevky E, Bell W. Social area analysis: theory, illustrative application and computational procedures. Stanford, CA: Stanford University Press, 1995.
31.
Scott-Samuel A. Social area analysis in community medicine. British Journal of Preventive and Social Medicine 1977;31:199–204PubMed
32.
33.
Adams PR, Martinez ME, Vickerie JL. Summary health statistics for the U.S. population: national health interview survey, 2009. Vital Health Statistics 2009;10(248):1–115
34.
Liao Y, Bang D, Cosgrove S, et al. Surveillance of health status in minority communities—racial and ethnic approaches to community health across the U.S. (REACH U.S.) risk factor survey, United States 2009. MMWR Surveillance Summary 2011;60(60):1–44.
35.
SAS Institute, Inc. SAS/STAT® 9.2 User’s Guide. Cary, NC: SAS Institute Inc.; 2008
36.
37.
Duhan D, Johnson S, Wilcox J, et al. Influences on consumer use of word-of-mouth recommendation sources. Journal of the Academy of Marketing Science 2007;25(4):283–95CrossRef
38.
Casadonte P. Community treatment programs take up buprenorphine. Science & Practice Perspectives 2004; 2(2):24–6.CrossRef
39.
Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients, Journal of General Internal Medicine 2007;22(4):527–30.PubMedCrossRef
40.
National Alliance of Advocates for Buprenorphine Treatment. National Alliance of Advocates for Buprenorphine Treatment (NAABT). Available online at www.​naabt.​org. Accessed March 28, 2013.
41.
Van Zee, A. The promotion and marketing of OxyContin: Commercial triumph, public health tragedy. Journal of the American Public Health Association 2009;99(2):221–7CrossRef
42.
43.
Egan JE, Casadonte P, Gartenmann T, et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. Journal of General Internal Medicine 2010;25(9):936–41.PubMedCrossRef
44.
Barry DT, Irwin KS, Jones ES, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. Journal of General Internal Medicine 2009;24(2):218–25PubMedCrossRef
45.
Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug and Alcohol Dependence 2009;99(1–3): 222–30PubMedCrossRef
46.
Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. Journal of Substance Abuse Treatment 2010;39(4):340–52PubMedCrossRef
47.
Sullivan LE, Moore BA, O’Connor PG, et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. American Journal of Addictions 2010;19(1):53–8CrossRef
48.
Link B. Epidemiological sociology and the social shaping of population health. Journal of Health and Social Behavior 2008;49:367–84PubMedCrossRef
49.
Rubin MS, Colen CG, Link G. Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective. American Journal of Public Health 2009;100(6):1053–9CrossRef
50.
Cutchin MP. The need for the “New Health Geography” in epidemiological studies of environment and health. Health Place 2007;13(3):725–42PubMedCrossRef
51.
52.
Metadata
Title
Variation in Use of Buprenorphine and Methadone Treatment by Racial, Ethnic, and Income Characteristics of Residential Social Areas in New York City
Authors
Helena B. Hansen, MD, PhD
Carole E. Siegel, PhD
Brady G. Case, MD
David N. Bertollo, BA
Danae DiRocco, MPH
Marc Galanter, MD
Publication date
01-07-2013
Publisher
Springer US
Published in
The Journal of Behavioral Health Services & Research / Issue 3/2013
Print ISSN: 1094-3412
Electronic ISSN: 2168-6793
DOI
https://doi.org/10.1007/s11414-013-9341-3

Other articles of this Issue 3/2013

The Journal of Behavioral Health Services & Research 3/2013 Go to the issue

OriginalPaper

The Impact of System Level Factors on Treatment Timeliness: Utilizing the Toyota Production System to Implement Direct Intake Scheduling in a Semi-rural Community Mental Health Clinic

OriginalPaper

Factor Structure of the Mental Health Statistics Improvement Program (MHSIP) Family and Youth Satisfaction Surveys

OriginalPaper

A Pilot Study Examining Trainee Treatment Session Fidelity when Parent–Child Interaction Therapy (PCIT) Is Implemented in Community Settings

OriginalPaper

Healthcare Cost Reductions Associated with the Use of LAI Formulations of Antipsychotic Medications Versus Oral Among Patients with Schizophrenia

OriginalPaper

Determinants of Successful Treatment Outcomes Among a Sample of Urban American Indians/Alaska Natives: the Role of Social Environments

OriginalPaper

Revolutionizing Child Welfare with Outcomes Management